NCX-470 is under clinical development by NicOx and currently in Phase III for Ocular Hypertension. According to GlobalData, Phase III drugs for Ocular Hypertension have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how NCX-470’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NCX-470 overview

NCX-470 is under development for the treatment of ocular hypertension and open angle glaucoma. The therapeutic candidate is administered through opthalmic route.The therapeutic candidate is a nitric oxide donating bimatoprost analog. It acts by targeting prostaglandin F2 alpha receptor and soluble guanylate cyclase.

NicOx overview

NicOx is an ophthalmology company developing solutions to help maintain vision and improve ocular health. The company carries out the research, development and marketing of investigational drugs for ophthalmological diseases. The company aims to produce therapeutic products which aim to address the needs of eye care practitioners and patients. The company’s product pipeline includes NCX 470 for glaucoma and VYZULTA, ZERVIATE and NCX 4251 for blepharitis and dry eye disease. The company has a presence across Germany, France, the United Kingdom, Italy and Spain. NicOx is headquartered in Valbonne, France.

For a complete picture of NCX-470’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.